Chugai Selected as a “Nadeshiko Brand” for FY2025
TOKYO, March 19, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it has been se...
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
TOKYO, March 19, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it has been se...
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical
Scope: Industry
Related coverage
More related coverage
Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
Approval based on the positive GLISTEN phase III trial with regulatory reviews underway in the EU, U...
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 w...
Chugai Files for the Medical Device Component of the Port Delivery Platform with ranibizumab in Japan
Application filed in Japan for the medical device component (ocular implant and ancillary devices) i...
Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions
Global data from over 12,000 consumers signals the future of modern aesthetics will be multimodal tr...